Posted by Michael Wonder on 17 Dec 2021
FDA approves new treatment for myasthenia gravis
17 December 2021 - The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor antibody.
The safety and efficacy of Vyvgart were evaluated in a 26-week clinical study of 167 patients with myasthenia gravis who were randomised to receive either Vyvgart or placebo.
